Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for AKBA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 209.81M
March 31, 2026 215.79M
December 31, 2025 212.75M
September 30, 2025 208.36M
June 30, 2025 204.93M
March 31, 2025 200.66M
December 31, 2024 189.25M
September 30, 2024 185.84M
June 30, 2024 99.44M
March 31, 2024 93.27M
December 31, 2023 99.69M
September 30, 2023 108.90M
June 30, 2023 110.51M
March 31, 2023 134.77M
December 31, 2022 152.52M
September 30, 2022 154.87M
June 30, 2022 186.63M
March 31, 2022 185.52M
December 31, 2021 184.32M
September 30, 2021 168.62M
June 30, 2021 167.75M
March 31, 2021 166.72M
December 31, 2020 121.00M
September 30, 2020 100.10M
June 30, 2020 101.20M
Date Value
March 31, 2020 102.28M
December 31, 2019 103.33M
September 30, 2019 28.81M
June 30, 2019 30.07M
March 31, 2019 31.30M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.014M
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.014M
September 30, 2015 0.002M
June 30, 2015 0.004M
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.0103M
March 31, 2014 0.0113M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Emergent BioSolutions, Inc. 586.70M
Exelixis, Inc. 165.93M
ADMA Biologics, Inc. 202.66M
Arcutis Biotherapeutics, Inc. 114.14M
Relay Therapeutics, Inc. 26.64M